Invited review<br>New cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment?

Olsen M, Sehestedt T, Hansen T, et al. Invited reviewNew cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment?. Archives of Medical Science Special Issues. 2009:242-242.

APA

Olsen, M., Sehestedt, T., Hansen, T., Christensen, M., Gustafsson, F.,  & Rasmussen, S. et al. (2009). Invited reviewNew cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment?. Archives of Medical Science Special Issues, 242-242.

Chicago

Olsen, Michael H., Thomas Sehestedt, Tine W. Hansen, Marina K. Christensen, Finn Gustafsson, Susanne Rasmussen,  and Kristian Wachtell et al. 2009. "Invited reviewNew cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment?". Archives of Medical Science Special Issues: 242-242.

Harvard

Olsen, M., Sehestedt, T., Hansen, T., Christensen, M., Gustafsson, F., Rasmussen, S., Wachtell, K., Ibsen, H., Torp-Pedersen, C.,  and Hildebrandt, P. (2009). Invited reviewNew cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment?. Archives of Medical Science Special Issues, pp.242-242.

MLA

Olsen, Michael H. et al. "Invited reviewNew cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment?." Archives of Medical Science Special Issues, 2009, pp. 242-242.

Vancouver

Olsen M, Sehestedt T, Hansen T, Christensen M, Gustafsson F, Rasmussen S et al. Invited reviewNew cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment?. Archives of Medical Science Special Issues. 2009:242-242.

We have tested the additive prognostic value of three relatively new, but established cardiovascular risk markers: N-terminal pro-brain natriuretic peptide (Nt-proBNP), related to haemodynamic cardiovascular risk factors, high sensitivity C-reactive protein (hsCRP), related to metabolic cardiovascular risk factors, and urine albumin/creatinine ratio (UACR), related to haemodynamic as well as metabolic risk factors. Furthermore, we have tested the prognostic importance of reduction of UACR during antihypertensive treatment. In healthy subjects with a 10-year risk of cardiovascular death lower than 5% based on HeartScore and therefore not eligible for primary prevention, the actual 10-year risk of cardiovascular death exceeded 5% in a small subgroup of subjects with UACR higher than the 95th percentile of approximately 1.6 mg/mmol. Combined use of high UACR or high hsCRP identified a larger subgroup of 16% with high cardiovascular risk in which primary prevention may be advised despite low-moderate cardiovascular risk based on HeartScore. Furthermore, combined use of high UACR or high Nt-proBNP in subjects with known cardiovascular disease or diabetes identified a large subgroup of 48% with extremely high cardiovascular risk who should be referred for specialist care in order to optimize treatment. Finally, reduction in UACR during antihypertensive treatment was associated with improved prognosis independently of changes in blood pressure and left ventricular hypertrophy. UACR and hsCRP improved risk stratification in low-risk subjects whereas UACR and Nt-proBNP improved risk stratification in high-risk subjects. Changes in UACR during antihypertensive treatment carried additive prognostic information.

keywords:

cardiovascular risk prediction, albumin/creatinine ratio, high sensitivity C-reactive protein, N-terminal pro brain natriuretic peptide, antihypertensive treatment

Invited reviewNew cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment?

Michael H. Olsen , Thomas Sehestedt , Tine W. Hansen , Marina K. Christensen , Finn Gustafsson , Susanne Rasmussen , Kristian Wachtell , Hans Ibsen , Christian Torp-Pedersen , Per R. Hildebrandt

cardiovascular risk prediction, albumin/creatinine ratio, high sensitivity C-reactive protein, N-terminal pro brain natriuretic peptide, antihypertensive treatment

Invited review
New cardiovascular risk markers in the general population and in hypertension. Do they improve risk prediction and influence treatment?

Michael H. Olsen

,

Thomas Sehestedt

,

Tine W. Hansen

,

Marina K. Christensen

,

Finn Gustafsson

,

Susanne Rasmussen

,

Kristian Wachtell

,

Hans Ibsen

,

Christian Torp-Pedersen

,

Per R. Hildebrandt